JPMorgan raised the firm’s price target on Novo Nordisk to DKK 950 from DKK 850 and keeps an Overweight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NVO:
- Amgen downgraded to Market Perform from Outperform at Leerink
- Novo Nordisk price target raised to $135 from $115 at TD Cowen
- M & A News: Novo Nordisk Announces $16.5B Catalent (NYSE:CTLT) Deal
- Catalent jumps 13% to $61.46 after Novo Holdings merger agreement
- Novo Holdings to sell three Catalent fill-finish sites after merger